In situ forming implants, defined as liquid formulations that generate solid or semisolid
depots following administration, have shown a range of advantages in drug delivery. This …

Long-acting injectable (LAIs) delivery systems sustain the drug therapeutic action in the
body, resulting in reduced dosage regimen, toxicity, and improved patient compliance. Lipid …

Background: The repair of osteoporotic bone defects remains challenging due to excessive
reactive oxygen species (ROS), persistent inflammation, and an imbalance between …

Tuberculosis (TB) is a communicable disease caused by Mycobacterium tuberculosis (Mtb)
and is a major cause of morbidity and mortality. Successful treatment requires strict …

Despite the unique advantages of injectable, long-acting in situ forming implant formulations
based on poly (lactide-co-glycolide)(PLGA) and N-Methyl-2-Pyrrolidone (NMP), only six …

In situ forming implants are attractive long-acting implant dosage forms due to their: i) ability
to control drug release; ii) simple manufacturing process; and iii) minimally invasive …

Perseris is a subcutaneous extended-release risperidone in situ forming implant
(suspension) indicated for the treatment of adult schizophrenia. Owing to the release rate …

Due to the versatility of the in situ forming implant (ISFI) drug delivery system, it is crucial to
understand the effects of formulation parameters for clinical translation. We utilized …

In situ forming implants (ISFI) based on poly (lactic-co-glycolic acid)(PLGA) are promising
long-acting injectable depots for the treatment of human immunodeficiency virus-1 infection …

In pancreatic cancer, excessive hyaluronic acid (HA) in the tumor microenvironment creates
a viscous stroma, which reduces systemic drug transport into the tumor and correlates with …